Does Trump's executive order automatically reschedule cannabis to Schedule III?

No. Executive Order 14370, signed December 18, 2025, directs Attorney General Pam Bondi to complete the formal DEA rulemaking process to reschedule marijuana from Schedule I to Schedule III — but it does not itself reschedule cannabis. The DEA must still publish and finalize a rule through the administrative process, which takes additional time even under presidential direction to proceed expeditiously. As Qredible CEO Brian Fitzpatrick explained, 'The executive order itself does not automatically reschedule cannabis. The DEA must still publish a final rule and the administrative process must be completed.' The order is a significant and directionally clear signal, but operators should understand that the signature alone changed nothing overnight.

When will cannabis businesses actually see 280E tax relief?

Cannabis businesses should plan for 280E relief to arrive in phases, not immediately. The 2025 tax year will not benefit — rescheduling will not be finalized in time. The 2026 tax year is possible but uncertain, depending on when the DEA publishes its final rule. The most realistic scenario for full-year 280E relief is the 2027 tax year, filed in 2028. Fitzpatrick's tax example illustrates the magnitude: a dispensary with $1 million revenue, $400K COGS, and $400K operating expenses currently pays taxes on $600K gross profit and keeps ~$74K after taxes. Without 280E, the same business pays taxes on $200K net income and keeps ~$158K — more than double the after-tax profit. Operators should also be aware of proposed legislation (HR147 / SB471, the No Deductions for Marijuana Business Act) that could complicate this timeline, though its passage likelihood is considered low.

Will Schedule III rescheduling allow pharmaceutical companies to take over state cannabis dispensaries?

No. This is one of the most persistent misconceptions about rescheduling. Fitzpatrick addressed it directly: 'Federal scheduling does not override state programs. State licensing frameworks remain completely unchanged. States will continue to license and regulate cannabis businesses exactly as they do today.' Three factors protect state dispensary operations. First, the federal Schedule III designation does not require state cannabis businesses to obtain DEA Schedule III registration — state-licensed dispensaries operate under state law and are not pharmacies. Second, states have powerful financial incentives to maintain their cannabis programs, which generate billions in tax revenue integral to state operating budgets. Third, the FDA approval pathway for pharmaceutical cannabinoid drugs (Epidiolex, Marinol, Syndros) already exists and has always been separate from state dispensary operations — Epidiolex required years of clinical trials and FDA approval; state dispensaries have never needed this.

How does Schedule III rescheduling expand cannabis research?

Currently, only approximately 600 researchers nationwide hold DEA registration for Schedule I substance research, due to extensive bureaucratic requirements — including special DEA review processes, stringent security and storage requirements, and access to only a very limited number of federally authorized cannabis suppliers. Schedule III dramatically reduces these barriers: researchers would register under a standard DEA process rather than the onerous Schedule I-specific pathway, access broader funding sources including institutional grants previously unavailable for Schedule I research, and conduct high-quality studies on dosing guidelines, safety profiles across different patient populations, and long-term health effects. Fitzpatrick viewed expanded research as one of the most significant positive developments: generating the scientific documentation that will ultimately support federal regulatory frameworks for cannabis products and legitimize the industry's long-term standing.

What should cannabis operators do right now to prepare for Schedule III rescheduling?

Fitzpatrick offered direct advice for operators looking to position for success: 'Get your house in order now. Be prepared for best practices-driven safety and standard certifications. Get involved with the ASTM D37 committee programs. Start your journey towards ISO or GMP certification now. Get in the fire prevention business and not the firefighting business.' Practically, this means: building and maintaining documented compliance infrastructure that satisfies the quality and safety standards that federal rescheduling will bring into sharper regulatory focus; preparing COA documentation, product testing records, and business licensing records in a systematized, audit-ready format; and investing in quality certifications now, using the 280E savings once they arrive as additional capital for compliance and quality improvements. The conversation in the cannabis industry has shifted, as Fitzpatrick noted, from 'should we' to 'how do we do this safely' — the operators who have already built compliance infrastructure will be positioned to lead when that moment arrives.

What Cannabis Schedule 3 Rescheduling Really Means for Your Business

Category: Business Learning Center Videos

Author: The Qredible Team

Date: December 30, 2025

The cannabis industry is buzzing with both excitement and confusion following President Trump's December 18th executive order, and for good reason. This marks the most significant federal cannabis policy shift in more than five decades. But what does cannabis schedule 3 rescheduling actually change for operators, and what remains the same?

During a recent Qredible Live Broadcast, Brian Fitzpatrick, CEO of Qredible, broke down the executive order in detail, separating fact from fiction and addressing the widespread anxiety circulating throughout the industry. His analysis provided critical clarity on timelines, tax implications, and why the "Big Pharma takeover" fears are largely unfounded.

"I want everybody to realize that this is a step. Okay, it's an important step in the right direction," Fitzpatrick explained. "This is how change actually happens in America folks. It's not revolutionary, okay? It's evolutionary."

Understanding What Schedule 3 Means

Cannabis currently sits in Schedule 1 of the Controlled Substances Act alongside heroin, LSD, psilocybin, and MDMA. The executive order directs Attorney General Pam Bondi to accelerate the process of moving cannabis to Schedule 3, placing it in the same category as testosterone and Tylenol with codeine.

"The most important thing here is the federal government now recognizes on paper, the paper being the executive order, that cannabis has accepted medical use and a lower abuse potential," Fitzpatrick noted.

However, he was quick to temper expectations: "This does not legalize cannabis federally. I want to make sure that everybody's aware of that. And it remains a controlled substance."

The executive order itself does not automatically reschedule cannabis. The DEA must still publish a final rule, and the administrative process must be completed. President Trump directed this to happen quickly, but operators should understand that the signature alone did not change anything overnight.

The 280E Tax Relief Opportunity

For many cannabis businesses, the elimination of IRS Section 280E represents the most significant financial benefit of rescheduling. Currently, 280E prohibits businesses trafficking in Schedule 1 or Schedule 2 substances from deducting ordinary business expenses.

Fitzpatrick illustrated the impact with a clear example: A dispensary with $1 million in revenue, $400,000 in cost of goods sold, and $400,000 in operating expenses currently pays taxes on $600,000 (gross profit) rather than $200,000 (net income). Under 280E, that business keeps $74,000 after taxes. Without 280E restrictions, that same business keeps $158,000.

"That's more than double the after-tax profit just from normal tax treatment," Fitzpatrick emphasized.

Realistic Timelines for Tax Benefits

Operators should approach 280E relief with cautious optimism. Fitzpatrick outlined the realistic timeline:

The 2025 tax year will not benefit from this change. The rescheduling simply will not be finalized in time. The 2026 tax year is possible but uncertain, depending on when the final rule is published. The most likely scenario for full-year benefits is the 2027 tax year, filed in 2028.

"The consensus is that generally tax changes are not retroactive and we'll have to see what the effective date is," Fitzpatrick explained. "I don't expect to see just generally they're not retroactive."

He also warned operators to monitor proposed legislation that could complicate matters, including the No Deductions for Marijuana Business Act (House Bill HR147 and Senate Bill 471), though he noted the likelihood of passage is low.

Debunking the Big Pharma Takeover Narrative

One of the most persistent fears in the cannabis community is that rescheduling to Schedule 3 will allow pharmaceutical companies to take over the industry, require prescriptions, and shut down dispensaries. Fitzpatrick addressed this concern directly.

"The reality here is that federal scheduling does not override state programs," he stated. "State licensing frameworks, however, remain completely unchanged. States will continue to license and regulate cannabis business exactly as they do today."

Why State Programs Are Protected

States have zero incentive to abandon their cannabis programs. These programs generate massive tax revenue that has become integral to state operating budgets. Eliminating them would mean billions in lost revenue and political consequences for lawmakers whose constituents voted for legalization.

Fitzpatrick compared the current situation to the Cole Memorandum era, where cannabis remained federally illegal but Washington allowed tightly regulated state programs to operate.

The FDA pathway for pharmaceutical cannabis products already exists and is entirely separate from state dispensary operations. Products like Epidiolex, Marinol, and Syndros are FDA-approved cannabinoid drugs that went through years of clinical trials. State dispensaries do not need FDA approval. They operate under state law, selling products like flower, gummies, and vapes that are regulated at the state level.

"Dispensaries are not pharmacies," Fitzpatrick clarified. "State-licensed dispensaries, they don't hold DEA registration to dispense Schedule 3 controlled substances."

Expanded Research and What It Means for Industry Legitimacy

The executive order specifically emphasizes expanding medical research, which Fitzpatrick views as a significant positive development. Currently, only about 600 researchers have registered with the DEA for Schedule 1 substance research due to extensive bureaucratic requirements.

Schedule 3 dramatically reduces these barriers, allowing researchers to access broader funding sources and conduct high-quality studies on dosing guidelines, safety profiles for different patient populations, and long-term health effects.

Prepare Your Business for What Comes Next

Fitzpatrick offered practical advice for operators looking to position themselves for success: "Get your house in order now. Be prepared for best practices-driven safety and standard certifications. Get involved with the ASTM D37 committee programs. Start your journey towards ISO or GMP certification now. Get in the fire prevention business and not the firefighting business."

The good news is that 280E relief, once it arrives, will provide additional capital to invest in compliance, quality, and safety improvements.

"The conversation has shifted from should we to how do we do this safely? And that's progress," Fitzpatrick concluded.

Watch the Full Episode

Want to dive deeper into the details of Trump's cannabis policy shift, including insights on banking reform, the SAFER Banking Act, and what's happening with hemp and CBD? Watch the full Qredible Live Broadcast with Brian Fitzpatrick to get the complete breakdown of what these changes mean for your business.